The disclosure relates to methods for treating tumors. In particular, the disclosure relates to a method of treating a tumor by magnetic resonance image-guided radiation therapy in a subject in need thereof, said method comprising the steps of: (i) administering an efficient amount of high-Z element containing nanoparticles having, contrast enhancement for magnetic resonance imaging and/or radiosensitizing properties for radiation therapy, in a subject in need thereof, and, (ii) exposing said subject to magnetic resonance image-guided radiation therapy by means of a Magnetic Resonance Imaging Guided Linear Accelerator (MR-Linac),
wherein said high-Z element containing nanoparticles are nanoparticles containing an element with an atomic Z number higher than 40, preferably higher than 50, and said nanoparticles have a mean hydrodynamic diameter below 20 nm, for example between 1 and 10 nm, preferably between 2 and 8 nm.

The dose and regimen of the sensitizer of the present invention which is effective for anticancer therapy for tumors and the schedule of the anticancer therapy, such as radiotherapy and anticancer chemotherapy, which is effective after administration of the sensitizer, are still unclear. The present inventors have demonstrated that the sensitizer for anticancer therapy, which is prepared by combining a specific range of concentration of H.sub.2O.sub.2 with a specific range of concentration of hyaluronic acid or a salt thereof in a specific amount, in a specific procedure, can be injected into the the affected tumor site to improve the effect of anticancer therapy such as radiation therapy and anticancer chemotherapy, thereby solving the above problems.

Disclosed is a method for increasing susceptibility of cancer cells to ionizing radiation by delivering to the cells a radiosensitizing agent that has one of the following properties: (a) it perturbs the process of chromosome segregation thereby increasing chromosome missegregation; or (b) it is an inhibitor of an agent that promotes faithful chromosome segregation induces numeric chromosome instability in said cells and this instability is induced substantially simultaneously with or closely prior to or closely after irradiating the cells. Examples of such radiosensitizing agent include inhibitors of one or more of the following: Kif2b, MCAK, MPS1, Eg5/Kinesin-5 5, Polo-like kinase 4, MCAK, Bub1 and Hec1. Such agents specifically target proteins involved in maintaining or promoting faithful chromosome segregation.

The invention concerns a dye for use in a method of photoporation of the inner limiting membrane (ILM) of an eye in a subject. Preferably, the method comprises: administering the dye to the vitreous chamber of the eye of the subject; and irradiating at least part of the ILM of the eye of the subject, thereby photoporating at least part of the ILM in the subject. The invention further relates to a dye and optionally a therapeutic agent for use in a method of treating a retinal disease or a choroidal disease of an eye in a subject.

This patent application relates to the treatment of cancer and other diseases that have a CD47+ phenotype. Treatment involves the use of radiation and a CD47-binding agent, preferably a CD47-binding form of human signal regulatory protein alpha (SIRPa) that inhibits activation of the CD47/SIRPa axis and mediates phagocytosis of CD47+ disease cells. An anti-cancer effect of a CD47 blocking agent is enhanced when combined with radiation therapy. The anti-cancer effect of a CD47 blocking agent such as SIRPaFc is enhanced when combined with radiation therapy.

The invention relates to a tantalum nanocomposite and a preparation method and application thereof, lymph tracer and radiosensitizer. The tantalum nanocomposite provided in the invention includes tantalum nanoparticle and bio-surfactant acting on the tantalum nanoparticle. The tantalum nanocomposite provided in the invention has good biosafety and can improve the effect of radiation therapy as a radiosensitizer.

Methods of treatment and treatment systems for performing radiomodulatory stereotactic radiosurgery to treat brain disorders in which target neural tissues associated with the brain disorder are sensitized to radiation by administration of a molecular substance and/or non-targeted critical structures are protected from radiation by a molecular substance, in order to treat disorders of brain circuitry. Specific embodiments disclose means for treating pain, obesity and drug addiction.

A fluorocarbon emulsion in water for use in fractionated radiotherapy and chemotherapy, wherein said fluorocarbon comprises between 4 and 8 carbon atoms.

Antifibrinolytic agents/drugs are applied to the concussive area of a patient's brain to counter the activation of a fibrinolytic process in the concussive area. Various techniques are described for administering the antifibrinolytic agent.

Method and kit for topical treatment of a skin infection, in particular of superficial skin infections, caused by Staphylococcus aureus. The method comprises the steps of applying a photosensitizer to at least a part of the skin affected by the infection, and subjecting said part of the skin to first photons with a majority energy between 2.8 eV and 3.5 eV at a first energy level; and second photons with a majority energy between 1.24 eV and 1.65 eV at a second energy level, the ratio between the first and the second energy levels being in the range from about 10:1 to 2:1. By the method efficient treatment of Staphylococcus aureus infections can be achieved without the administration of topical antibiotics.